Table 1.
Summary of the characteristics of the included studies
| Study | Institution no. | Patients | Index test | Period | Age, mean (range) | Men (%) |
NMIBC (%) | Tumour lesions (n) |
| Shadpour et al 31 | Unicentre | 50 | NBI | 2012–2013 | 63.86±10.05 | 34 (68.0) | 100 | 95 |
| Song et al 29 | Unicentre | 63 | NBI | 2012–2013 | 66(56-76) | 39 (61.9) | 94.1 | 21 |
| Kobatake et al 36 | Unicentre | 135 | NBI | 2010–2014 | 75 | 110 (81.5) | 100 | 120 |
| Ye et al 11 | Multicentre | 384 | NBI | NR | 61(21-79) | 267 (69.5) | 100 | 167 |
| Shen et al 30 | Unicentre | 78 | NBI | 2009–2010 | 68 (33–75) | 62 (79.5) | 100 | 211 |
| Zhu et al 26 | Unicentre | 12 | NBI | 2009–2010 | 57(28-73) | 9 (75.0) | 100 | 9 |
| Tatsugami et al 28 | Unicentre | 104 | NBI | 2007–2009 | 70.6 (38–90) | 88 (84.6) | NR | 110 |
| Cauberg et al 47 | Multicentre | 95 | NBI | 2007–2009 | 70.6 (38.1–90.2) | 70 (73.7) | NR | 226 |
| Herr and Donat39 | Unicentre | 427 | NBI | 2007 | 65 (26–90) | 316 (74.0) | 100 | NR |
| Palou et al 34 | Multicentre | 283 | HAL | 2008–2009 | 67.5 (42–95) | 242 (85.5) | 94.1 | 621 |
| Lapini et al 35 | Multicentre | 96 | HAL | 2010–2011 | NR | 80 (83.3) | NR | 108 |
| Burgués et al 48 | Multicentre | 305 | HAL | 2006–2009 | 66.9 (39–93) | 270 (88.5) | 100 | 600 |
| Ray et al 15 | Unicentre | 27 | HAL | 2005–2006 | 70(49-82) | 21 (77.8) | 100 | NR |
| Schmidbauer et al 32 | Unicentre | 66 | HAL | NR | 63(38-84) | 49 (74.2) | 93.1 | NR |
| Geavlete et al 40 | Unicentre | 128 | HAL | 2007–2008 | 65(36-81) | NR | 92.2 | NR |
| Fradet et al 41 | Multicentre | 298 | HAL | NR | 67±11 | 223 (74.8) | 100 | 113 |
| Jichlinski et al 37 | Multicentre | 52 | HAL | 2000–2001 | 72±12 | 38 (73.1) | 100 | 143 |
| Grimbergen et al 5 | Unicentre | 160 | 5-ALA | 1998–2002 | 67(30-91) | NR | 90.0% | 390 |
| Filbeck et al 43 | Unicentre | 279 | 5-ALA | 1997–2000 | 34–89 | NR | 90.3% | 336 |
| Dominicis et al 45 | Unicentre | 49 | 5-ALA | NR | 60(31-77) | 42 (85.7) | 100 | 52 |
| Ehsan et al 44 | Unicentre | 30 | 5-ALA | NR | 55–89 | 19 (63.3) | NR | NR |
| Jeon et al 38 | Unicentre | 62 | 5-ALA | 1997–1999 | 61.9 (32–80) | 57 (91.1) | NR | 148 |
| Zaak et al 27 | Unicentre | 605 | 5-ALA | NR | 65.6 (16–99) | 472 (78.0) | NR | 552 |
| Filbeck et al 42 | Unicentre | 123 | 5-ALA | 1997 | 64.5 (28–86) | NR | 91.9 | 124 |
| Riedl et al 33 | Unicentre | 52 | 5-ALA | NR | 44–79 | NR | 100 | 123 |
| D'Hallewin et al 46 | Unicentre | 16 | 5-ALA | NR | NR | NR | 100 | 50 |
5-ALA, 5-aminolaevulinic acid; HAL, hexylaminolevulinate; NBI, narrow band imaging;NMIBC, non-muscle invasive bladder cancer; NR, not reported; NT, new technology.